Celadon Pharmaceuticals (LSE:CEL) Growth Rank : 0 (As of May. 22, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Celadon Pharmaceuticals Growth Rank?

Celadon Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Celadon Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of Celadon Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Celadon Pharmaceuticals (LSE:CEL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Celadon Pharmaceuticals PLC (LSE:CEL) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

32-33 Cowcross Street, London, GBR, EC1M 6DF

Website

https://www.celadonpharma.co.uk

Celadon Pharmaceuticals PLC focuses on growing indoor hydroponic high-quality cannabis initially for use within the chronic pain market. It has two reportable segments Celadon is a Build of grow facilities, growing medical grade cannabis and research in the GMP lab, and Harley Street (CPC) is a clinical study into the pain relief benefits of medicinal cannabis.

Celadon Pharmaceuticals (LSE:CEL) Headlines

No Headlines